These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 35033999)
1. Canadian Adalimumab Postmarketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis (COMPLETE-PsA): 12-month Results of Comparative Effectiveness of Adalimumab and nbDMARDs. Khraishi MM; Remple VP; Silverberg S; Stewart JC; Florica B; Bessette L J Rheumatol; 2022 May; 49(5):454-464. PubMed ID: 35033999 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness of early adalimumab therapy in psoriatic arthritis patients from Reuma.pt - EARLY PsA. Santos H; Eusébio M; Borges J; Gonçalves D; Ávila-Ribeiro P; Faria DS; Lopes C; Rovisco J; Águeda A; Nero P; Valente P; Cravo AR; Santos MJ Acta Reumatol Port; 2017; 42(4):287-299. PubMed ID: 29342473 [TBL] [Abstract][Full Text] [Related]
3. Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study. Gladman DD; ; Sampalis JS; Illouz O; Guérette B J Rheumatol; 2010 Sep; 37(9):1898-906. PubMed ID: 20595284 [TBL] [Abstract][Full Text] [Related]
4. Real-world data on change in work productivity, activity impairment, and quality of life in patients with psoriatic arthritis under anti-TNF therapy: a postmarketing, noninterventional, observational study. Karadag O; Dalkilic E; Ayan G; Kucuksahin O; Kasifoglu T; Yilmaz N; Koca SS; Yazisiz V; Erten PT; Sayarlioglu M; Terzioglu ME; Erten S; Kalyoncu U Clin Rheumatol; 2022 Jan; 41(1):85-94. PubMed ID: 34477993 [TBL] [Abstract][Full Text] [Related]
5. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52. Smolen JS; Mease P; Tahir H; Schulze-Koops H; de la Torre I; Li L; Hojnik M; Sapin C; Okada M; Caporali R; Gratacós J; Goupille P; Liu Leage S; Pillai S; Nash P Ann Rheum Dis; 2020 Oct; 79(10):1310-1319. PubMed ID: 32660977 [TBL] [Abstract][Full Text] [Related]
6. Real-World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients with Psoriatic Arthritis. Nakagawa H; Tanaka Y; Sano S; Kameda H; Taniguchi A; Kashiwagi T; Kawaberi T; Kimura J; Morita A Adv Ther; 2019 Mar; 36(3):691-707. PubMed ID: 30661197 [TBL] [Abstract][Full Text] [Related]
7. Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Rahman P; McInnes IB; Deodhar A; Schett G; Mease PJ; Shawi M; Cua DJ; Sherlock JP; Kollmeier AP; Xu XL; Sheng S; Ritchlin CT; McGonagle D Clin Rheumatol; 2024 May; 43(5):1591-1604. PubMed ID: 38472528 [TBL] [Abstract][Full Text] [Related]
8. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Mease PJ; Smolen JS; Behrens F; Nash P; Liu Leage S; Li L; Tahir H; Gooderham M; Krishnan E; Liu-Seifert H; Emery P; Pillai SG; Helliwell PS; Ann Rheum Dis; 2020 Jan; 79(1):123-131. PubMed ID: 31563894 [TBL] [Abstract][Full Text] [Related]
9. Results of one-year treat-to-target strategy in early psoriatic arthritis: data of an open-label REMARCA study. Korotaeva TV; Loginova EY; Getiya TS; Nasonov EL Ter Arkh; 2018 May; 90(5):22-29. PubMed ID: 30701886 [TBL] [Abstract][Full Text] [Related]
10. Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. Ritchlin CT; Mease PJ; Boehncke WH; Tesser J; Chakravarty SD; Rampakakis E; Shawi M; Schiopu E; Merola JF; McInnes IB; Deodhar A Clin Rheumatol; 2024 Aug; 43(8):2551-2563. PubMed ID: 38844682 [TBL] [Abstract][Full Text] [Related]
11. Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Atteno M; Peluso R; Costa L; Padula S; Iervolino S; Caso F; Sanduzzi A; Lubrano E; Del Puente A; Scarpa R Clin Rheumatol; 2010 Apr; 29(4):399-403. PubMed ID: 20066450 [TBL] [Abstract][Full Text] [Related]
12. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Gladman DD; Mease PJ; Cifaldi MA; Perdok RJ; Sasso E; Medich J Ann Rheum Dis; 2007 Feb; 66(2):163-8. PubMed ID: 17046964 [TBL] [Abstract][Full Text] [Related]
13. Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care. Ørnbjerg LM; Rugbjerg K; Georgiadis S; Rasmussen SH; Jacobsson L; Loft AG; Iannone F; Fagerli KM; Vencovsky J; Santos MJ; Möller B; Pombo-Suarez M; Rotar Z; Gudbjornsson B; Cefle A; Eklund K; Codreanu C; Jones G; van der Sande M; Wallman JK; Sebastiani M; Michelsen B; Závada J; Nissen MJ; Sanchez-Piedra C; Tomšič M; Love TJ; Relas H; Mogosan C; Hetland ML; Østergaard M J Rheumatol; 2024 Apr; 51(4):378-389. PubMed ID: 38224992 [TBL] [Abstract][Full Text] [Related]
14. Clinical remission in patients with active psoriatic arthritis treated with adalimumab and correlations in joint and skin manifestations. Van den Bosch F; Kavanaugh A; Kron M; Kupper H; Mease PJ J Rheumatol; 2015 Jun; 42(6):952-9. PubMed ID: 25834212 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2. McInnes IB; Chakravarty SD; Apaolaza I; Kafka S; Hsia EC; You Y; Kavanaugh A RMD Open; 2019; 5(2):e000990. PubMed ID: 31565242 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Van den Bosch F; Manger B; Goupille P; McHugh N; Rødevand E; Holck P; van Vollenhoven RF; Leirisalo-Repo M; Fitzgerald O; Kron M; Frank M; Kary S; Kupper H Ann Rheum Dis; 2010 Feb; 69(2):394-9. PubMed ID: 19815494 [TBL] [Abstract][Full Text] [Related]
17. Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52. Behrens F; Leage SL; Sapin C; Baou CE; De La Torre I; Meszaros G; Schett G; Combe B; van den Bosch F; Gossec L Clin Rheumatol; 2021 Dec; 40(12):4943-4954. PubMed ID: 34515902 [TBL] [Abstract][Full Text] [Related]
18. Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy. Furst DE; Kavanaugh A; Florentinus S; Kupper H; Karunaratne M; Birbara CA Rheumatology (Oxford); 2015 Dec; 54(12):2188-97. PubMed ID: 26199453 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study. Scrivo R; Castellani C; Mancuso S; Sciarra G; Giardina F; Bevignani G; Ceccarelli F; Spinelli FR; Alessandri C; Di Franco M; Riccieri V; Priori R; Conti F Clin Exp Rheumatol; 2023 Mar; 41(3):613-619. PubMed ID: 35916302 [TBL] [Abstract][Full Text] [Related]
20. Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry. Rahman P; Zummer M; Bessette L; Baer P; Haraoui B; Chow A; Kelsall J; Kapur S; Rampakakis E; Psaradellis E; Lehman AJ; Nantel F; Osborne B; Tkaczyk C BMJ Open; 2017 Aug; 7(8):e016619. PubMed ID: 28855200 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]